URGENT MEDICAL CASE: CRISPR Autovaccination for Metastatic Ewing Sarcoma

Time-sensitive clinical case of a 21-year-old female with metastatic Ewing Sarcoma (EWSR1-FLI1 fusion-positive), currently experiencing active CNS progression. All standard treatments (chemotherapy, surgery, radiotherapy) have been exhausted. This patient is a candidate for immediate application of CRISPR-induced autovaccination, utilizing fully open-source therapeutic architectures: CRISPR Autovaccination v3.0 DOI: 10.5281/zenodo.17246573 Triggered Therapy Platform (TTP) v3.0 DOI: 10.5281/zenodo.17237907 An Integrated Bioengineering Architecture for Ewing Sarcoma: CRISPR-Cas9 Autovaccination Coupled with a Temporally Programmed Delivery DOI: 10.5281/zenodo.17308401 Critical Timeline Treatment must begin by October 2025. The patient’s condition is actively deteriorating, including new CNS lesions. Delay significantly reduces feasibility of intervention. Collaboration Urgently Needed Seeking immediate collaboration with: Cell therapy laboratories (for dendritic cell engineering) CRISPR/gene editing specialists Oncology clinics with capacity for compassionate use Experts in regulatory and ethical implementation Open Access All referenced therapeutic frameworks are published under the Creative Commons Zero (CC0) license.There are no patents, no restrictions, and no legal barriers to clinical implementation.This case may represent the first clinical use of open-source CRISPR immunotherapy. Contact:Alexey Mikhailovich BurlaiEmail: [email protected]: 0009-0001-4679-5967